Akebia Europe

Akebia Therapeutics is a fully integrated biopharmaceutical company dedicated to developing and commercializing novel therapeutics for patients with kidney disease. The company's lead product, Vafseo (vadadustat), is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved for treating anemia due to chronic kidney disease. Akebia also markets Auryxia (ferric citrate) for hyperphosphatemia and iron deficiency anemia in the United States. The company is expanding its focus into rare kidney diseases with a pipeline that includes praliciguat, a soluble guanylate cyclase (sGC) stimulator, and AKB-097, a tissue-targeted complement inhibitor. Headquartered in Cambridge, Massachusetts, Akebia operates globally through strategic partnerships in Europe, Japan, and other regions.